Compare Eli Lilly And Co (LLY) vs Palo Alto Networks Inc (PANW) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Palo Alto Networks (PANW) trades at $353.85, down 1.35% on the day but showing strong bullish momentum with shares roughly doubling over three months. The stock exhibits robust fundamentals with consistent earnings beats, revenue growth to $9.22B in 2025, and a high gross margin of 71.94%. Technical indicators signal a bullish trend, supported by positive moving averages, though RSI levels suggest potential overbought conditions near-term.

Outlook remains positive driven by AI-driven cybersecurity demand and platformization strategy, but high valuation ratios (P/E 311.9, P/S 24.9) pose risks. Analyst consensus is strongly bullish (74% Buy ratings) with a $339.56 price target, though competition and integration costs are key watchpoints for investors.